Baidu
map

Esperion的ATP柠檬酸裂解酶抑制剂Nexletol,获FDA批准治疗心血管疾病

2020-02-25 不详 MedSci原创

美国生物制药公司Esperion的ATP柠檬酸裂解酶(ACL)抑制剂Nexletol(bempedoic acid),获得FDA批准用作动脉粥样硬化性心血管疾病(ASCVD)或杂合家族性高胆固醇血症(HeFH)患者他汀类药物的补充疗法。

美国生物制药公司Esperion的ATP柠檬酸裂解酶(ACL)抑制剂Nexletol(bempedoic acid),获得FDA批准用作动脉粥样硬化性心血管疾病(ASCVD)或杂合家族性高胆固醇血症(HeFH)患者他汀类药物的补充疗法。

Esperion报告了Nexletol2230名ASCVD和HeFH患者中的试验结果,结果表明,将这种药物添加到他汀类药物后,可显着降低LDL-胆固醇和炎症生物标志物C反应蛋白的水平。

Jefferies的分析师表示,Nexletol可能会占领多达四分之一的胆固醇药物市场,并有望达到20亿至30亿美元的峰值销售额。

该公司还向欧洲提交了Nexletol的申请,以及Nexletol与ezetimibe复方制剂向FDA和EMA的申请。

由他汀类药物主导多年的心血管疾病市场,可能在近两年将会涌入新型药物--Amgen和Sanofi / Regeneron的可注射PCSK9抑制剂,以及诺华的siPCSK9基因沉默药物,每年仅需给药两次。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-04-19 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-10-07 shenxlcyp
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-07-10 jklm09
  6. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-06-03 bugit
  7. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
    2020-02-27 listen320
  8. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1780243, encodeId=c5e21e80243d2, content=<a href='/topic/show?id=eafb29e391' target=_blank style='color:#2F92EE;'>#ATP柠檬酸裂解酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2973, encryptionId=eafb29e391, topicName=ATP柠檬酸裂解酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 10 17:24:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728319, encodeId=f0b51e28319d7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 06:24:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709793, encodeId=081b1e09793dc, content=<a href='/topic/show?id=128e904112c' target=_blank style='color:#2F92EE;'>#裂解酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90411, encryptionId=128e904112c, topicName=裂解酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c96b31789917, createdName=12498cbcm10(暂无昵称), createdTime=Mon May 25 12:24:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785839, encodeId=048b1e8583911, content=<a href='/topic/show?id=d4dfe035e3' target=_blank style='color:#2F92EE;'>#ESPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7035, encryptionId=d4dfe035e3, topicName=ESPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Oct 07 20:24:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852280, encodeId=f141185228003, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 10 23:24:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839770, encodeId=bba51839e70e2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Jun 03 17:24:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461674, encodeId=e74114616e4df, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498697, encodeId=f58f149869edc, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542159, encodeId=22e2154215974, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Thu Feb 27 09:24:00 CST 2020, time=2020-02-27, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map